Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients

AIM: To estimate the mean lifetime survival benefit, an essential component of health economic evaluations in oncology, of adding tumor treating fields (TTFields) to maintenance temozolomide (TMZ) for newly diagnosed glioblastoma patients. METHODS: We integrated EF-14 trial data with glioblastoma ep...

Descripción completa

Detalles Bibliográficos
Autores principales: Guzauskas, Gregory F, Salzberg, Marc, Wang, Bruce CM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200060/
https://www.ncbi.nlm.nih.gov/pubmed/30124334
http://dx.doi.org/10.2217/cns-2018-0010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200060/
https://www.ncbi.nlm.nih.gov/pubmed/30124334
http://dx.doi.org/10.2217/cns-2018-0010

Ejemplares similares